Home>Topics>Stocks>Alexza Pharmaceuticals

Alexza Pharmaceuticals ALXA

  1. All
  2. Commentary
  3. Headlines
    1. Alexa completes stocking for Adasuve launch in U.S.

      Headlines

      Thu, 9 Oct 2014

      Alexza Pharmaceuticals ( ALXA -0.5% ) completes the initial stocking of Adasuve (loxapine) inhalation powder (Staccato loxapine) for the U.S. launch

    2. Alexza to report on November 5

      Headlines

      Wed, 8 Oct 2014

      Alexza Pharmaceuticals ( ALXA -2.6% ) will report Q3 results on November 5 after the close. The conference call will begin at 5:00 m ET. Consensus view is a loss of ($0.77) per share on revenues of $3.2M. Post your comment!

    3. Alexza resubmits drug application early, shares soar

      Headlines

      Fri, 22 Jun 2012

      (Reuters) - Alexza Pharmaceuticals Inc resubmitted the marketing application for its anti-agitation treatment earlier than expected, sending its shares up as much as 47 percent.

    4. Setback for Valeant's Drug Candidate Adusuve Staccato

      Commentary

      Mon, 11 Oct 2010

      Valeant Pharmaceuticals VRX announced Monday that its partner Alexza Pharmaceuticals ALXA received a complete response letter on drug candidate adusuve staccato (formerly known as staccato loxapine). We will maintain

    5. Dropping Coverage of Alexza

      Commentary

      Mon, 7 Sep 2009

      We are no longer providing equity research on Alexza Pharmaceuticals ALXA . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    6. Alexza to Acquire Longtime Partner

      Commentary

      Tue, 16 Jun 2009

      Alexza Pharmaceuticals ALXA announced that it has exercised its option to purchase longtime partner Symphony Allegro in a deal expected to close in the third

    7. Cash Still a Concern for Alexza

      Commentary

      Fri, 8 May 2009

      Despite Alexza Pharmaceuticals ' ALXA success at narrowing its net loss for the first quarter, we are keeping our fair value estimate in place because of our continuing

    8. Alexza under Review

      Commentary

      Fri, 30 Jan 2009

      We are putting Alexza Pharmaceuticals ALXA under review after the firm announced that it will reduce its workforce by 33% and halt certain early-stage drug-development

    9. Positive Phase III Data for Alexza

      Commentary

      Wed, 10 Dec 2008

      Alexza Pharmaceuticals ALXA announced positive results from its second Phase III trial of its lead antipsychotic drug, AZ-004, for treatment of acute agitation

    10. Lowering Alexza's Uncertainty Rating

      Commentary

      Tue, 18 Nov 2008

      We're lowering Alexza Pharmaceuticals ' ALXA fair value uncertainty rating. Although we believe the company still represents a very speculative investment, we don't feel

    « Prev12Next »
    Content Partners